Last SFr.17.35 CHF
Change Today +0.25 / 1.46%
Volume 20.0K
NWRN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
OTC US
As of 11:43 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

newron pharmaceuticals spa (NWRN) Snapshot

Open
SFr.17.20
Previous Close
SFr.17.10
Day High
SFr.17.50
Day Low
SFr.17.00
52 Week High
11/18/13 - SFr.19.50
52 Week Low
09/3/13 - SFr.8.51
Market Cap
225.9M
Average Volume 10 Days
24.7K
EPS TTM
SFr.-0.61
Shares Outstanding
13.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEWRON PHARMACEUTICALS SPA (NWRN)

Related News

No related news articles were found.

newron pharmaceuticals spa (NWRN) Related Businessweek News

No Related Businessweek News Found

newron pharmaceuticals spa (NWRN) Details

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain. Its lead product is safinamide that has completed Phase III trials for the treatment of patients with Parkinson’s disease. The company also has a pipeline of novel drug candidates in Phase II trials, which include sNN0031 for the treatment of Parkinson’s disease patients, sNN0029 for the treatment of amyotrophic lateral sclerosis, and Sarizotan for the treatment of Rett’s syndrome. In addition, it develops NW-3509 that is in Phase I trials for the treatment of schizophrenia; and ralfinamide, which is in Phase II trials for the treatment of neuropathic pain. It has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development of safinamide in Japan and Asia. Newron Pharmaceuticals S.p.A. was founded in 1998 and is headquartered in Bresso, Italy.

23 Employees
Last Reported Date: 03/4/14
Founded in 1998

newron pharmaceuticals spa (NWRN) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €390.0K
Chief Medical Officer
Total Annual Compensation: €752.0K
Compensation as of Fiscal Year 2013.

newron pharmaceuticals spa (NWRN) Key Developments

Newron Pharmaceuticals S.p.A. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014

Newron Pharmaceuticals S.p.A. Presents at ROTH Healthcare Corporate Access Day - London, Jun-24-2014 . Venue: The Dorchester, 3 Tilney Street, London, W1K 1BJ, United Kingdom.

Newron Pharmaceuticals S.p.A. and Zambon Company S.p.A. Announces Safinamide New Drug Application Submitted to the US Food and Drug Administration

Newron Pharmaceuticals S.p.A. and its partner Zambon S.p.A. announced that the New Drug Application for safinamide was submitted to the US Food and Drug Administration. The submission covers the indications "safinamide as add-on therapy to a stable dose of a single dopamine agonist" in early Parkinson's disease patients and "safinamide as add-on therapy to levodopa alone or in combination with other Parkinson's disease treatments" in mid-to late stage Parkinson's disease patients. The submission was based on completion of activities agreed upon during meetings with the FDA. The submission was made by Newron, which is the NDA holder until completion of the sublicense process for the US rights to safinamide, by Zambon.

Newron Pharmaceuticals S.p.A. Presents at BioEquity Europe 2014, May-22-2014 12:00 PM

Newron Pharmaceuticals S.p.A. Presents at BioEquity Europe 2014, May-22-2014 12:00 PM. Venue: Hilton Amsterdam Hotel, Amsterdam, Netherlands.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NWRN:SW SFr.17.35 CHF +0.25

NWRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NWRN.
View Industry Companies
 

Industry Analysis

NWRN

Industry Average

Valuation NWRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 45.2x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWRON PHARMACEUTICALS SPA, please visit www.newron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.